Conservative management of grade 2 stage IA endometrial carcinoma and literature review. Issue 3 (5th January 2021)

• Record Type: Journal Article
• Authors: Shan, Weiwei; Wu, Pengfei; Yang, Bingyi; Zhang, Hongwei; Sun, Li; Lv, Qiaoying; Luo, Xuezhen; Cheng, Yali; Zhu, Qin; Chen, Xiaojun
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 47:Issue 3(2021)
• Page Start: 984
• Page End: 991
• Publication Date: 2021-01-05
• Subjects: fertility‐sparing treatment -- grade 2 endometrial cancer -- megestrol acetate; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.14646
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Purpose: To explore the clinical outcomes of megestrol acetate alone or plus metformin in young women with grade 2 stage IA endometrial carcinoma who ask for preserved fertility. Methods: Patients with stage IA grade 2 endometrial carcinoma who asked for fertility‐sparing treatment in the Obstetrics and Gynecology Hospital of Fudan University between 2015 and 2017 were enrolled and retrospectively reviewed. Results: Four patients were included and treated with oral megestrol acetate (160 mg per day), while metformin (500 mg, thrice daily) was added for patients with metabolic syndrome. Regular hysteroscopic examination was performed every 3 months during the conservative treatment. Overall, 75% (3/4) of the patients had a complete response, one relapsed and achieved a complete response after changing the therapy plan, and one patient had an indication of myometrial invasion during fertility‐sparing treatment and chose to remove uterus. Conclusions: Fertility‐sparing treatment for stage IA grade 2 endometrial carcinoma patients is worth exploration. Megestrol acetate with or without metformin combined with hysteroscopic lesion ablation may be an effective therapy.